Tenon Medical, Inc. (TNON) Company Overview

Tenon Medical, Inc. is a U.S. medical-device company focused narrowly on disorders of the sacroiliac joint, the load-bearing joint that connects the spine and pelvis. The company was incorporated in Delaware in 2012, is headquartered in Los Gatos, California, and trades on the Nasdaq Capital Market under TNON. Its investor-relations site identifies the listing and provides current filings and corporate updates.

Why is the SI-joint opportunity strategically interesting?

Tenon’s 2025 Form 10-K estimates that more than 30 million U.S. adults have chronic lower-back pain and cites studies associating 15% to 30% of that pain with the SI joint. The filing also estimates that surgical penetration is only 5% to 7%. These are company estimates rather than audited market-share data, but they explain management’s thesis: diagnosis is common enough to support a meaningful market, while surgical treatment remains underpenetrated.

The company is not dominant today. It is an early commercial-stage challenger trying to build credibility around differentiated surgical access, fusion principles and clinical evidence. That distinction is essential: Tenon matters because it is attempting to broaden how SI-joint fusion is performed, not because it already controls the category.

Tenon earns product revenue when Catamaran or SImmetry+ implants and related procedure components are used in surgery. The customer is generally a hospital or medical facility, while the clinician chooses and performs the procedure. Revenue is recognized when the product has been delivered and the surgery is completed, net of rebates and discounts. Standard direct-customer payment terms are generally 30 days.

Which revenue drivers matter most?

What determines gross margin?

Tenon uses contract manufacturers for implants, tray sets and instruments. Cost of goods sold includes components, operations overhead, tray depreciation, inspection, packaging, scrap, obsolescence, logistics and shipping. That creates an important scale effect: as procedure volume rises, fixed production overhead is spread across more revenue. The same model also exposes the company to supplier lead times, quality problems and purchasing-cost inflation.

The latest fully reported period is the quarter ended March 31, 2026. Tenon’s first-quarter 2026 earnings release and Form 10-Q show rapid top-line growth and a substantially better gross margin, but also continued operating losses and dependence on external financing.

Where did the improvement come from?

Revenue increased from $0.726 million in Q1 2025 to $1.379 million in Q1 2026. Management attributed the gain to more surgical procedures, continued Catamaran adoption and the addition of SImmetry+ revenue after the August 2025 acquisition. Gross profit rose from $0.323 million to $0.945 million, while gross margin expanded from 44.5% to 68.5%. The filing explains that higher volume absorbed production overhead more efficiently.

Why is profitability still distant?

Sales and marketing expense was $1.858 million, general and administrative expense was $1.705 million and R&D was $0.662 million in Q1 2026. Tenon also trained 21 physicians during the quarter. Those investments may support future cases, but current gross profit does not yet cover the commercial and public-company cost base.

Tenon’s strategic logic is to offer more than one minimally invasive route to SI-joint fusion. Catamaran uses an inferior-posterior approach with a single titanium implant designed to transfix the ilium and sacrum. SImmetry+ uses lateral access, joint decortication, bone-graft placement and threaded 3D-printed titanium implants. The portfolio therefore addresses surgeon preference and patient anatomy through different access paths while retaining the orthopedic objective of fixation plus biological fusion.

What regulatory and clinical evidence supports the portfolio?

Catamaran first received FDA clearance in 2018. The FDA’s official database records a further Catamaran decision under 510(k) K260477 on April 8, 2026. For SImmetry+, the EVoluSIon prospective multicenter study enrolled up to 250 patients; the 2025 10-K reports that approximately 69% had radiographic evidence of fusion on CT at 12 months, alongside improvements in pain and disability.

Tenon also reports IRB approval for a 50-patient, 10-center multicenter trial and a prospective CT study associated with Catamaran. Post-market evidence matters because 510(k) clearance establishes substantial equivalence, but clinicians and payors may still require convincing data on outcomes, workflow, safety and fusion.

How important is intellectual property?

Tenon’s history is best understood as a sequence of product, commercialization and financing decisions rather than a conventional scale-up. Each turning point changed either the addressable procedure set, the commercial platform or the capital structure.

1. 2012
   Tenon was incorporated and began developing a dedicated SI-joint fixation platform.
2. 2018
   Catamaran received its initial FDA 510(k) clearance, moving the company from development toward commercialization.
3. April 2022
   The IPO raised approximately $13.8 million net and placed TNON on Nasdaq, but also introduced public-company overhead and future dilution risk.
4. October 2022
   Tenon launched Catamaran nationally, shifting the key question from regulatory clearance to surgeon adoption and procedure growth.
5. August 2025
   The SiVantage and SIMPL Medical asset acquisition added SImmetry+, a second surgical approach and a larger clinical evidence base.
6. March–July 2026
   Convertible notes and a $4.2 million public offering funded operations while increasing the importance of dilution, maturity and Nasdaq-compliance analysis.

What did the 2025 acquisition change?

The acquisition reduced Tenon’s dependence on one approach and brought senior commercial and innovation personnel into the organization. It also created contingent consideration and equity issuance. In April 2026, acquired-product sales reached a $1 million aggregate milestone, and Tenon issued 276,228 common shares to SiVantage on May 1, 2026. The acquisition therefore strengthened the product story while adding integration, inventory and dilution considerations.

Tenon’s 2025 10-K identifies SI-BONE, Globus Medical, Medtronic, Xtant Medical and RTI Surgical as primary U.S. competitors. These companies vary materially in scale, distribution and portfolio breadth. SI-BONE is the most direct dedicated-category comparison, while the larger orthopedic companies can bundle SI-joint products into broader hospital and surgeon relationships.

What resources could become durable advantages?

These ratings are analytical, not company disclosures. The strongest potential moat is the combination of two access approaches, procedure-specific know-how, patents and clinical evidence. The weakest link is scale. A technology can be clinically useful yet fail commercially if surgeons are not trained, hospitals do not approve it, reimbursement is uncertain or inventory is unavailable.

Where is the moat most vulnerable?

Large competitors can use broader portfolios, established sales forces, contracting relationships and research budgets to defend share. Tenon also acknowledges that new entrants and alternative procedures may intensify price pressure. Tenon’s differentiation must therefore produce observable clinical or workflow value, not merely a different implant design.

The income statement is improving at the gross-profit level, but Tenon remains financially fragile. FY2025 revenue increased 20% to $3.944 million, gross profit increased 38% to $2.358 million and gross margin rose to 60% from 52% in FY2024. Yet FY2025 operating expenses were $15.150 million and the net loss was $12.556 million. The company has never generated positive operating cash flow.

What do cash burn and financing imply?

At March 31, 2026, cash and cash equivalents were $4.607 million, stockholders’ equity was $1.895 million and the accumulated deficit was $84.778 million. Q1 operating cash outflow was $2.960 million and capital spending was $0.056 million, implying negative free cash flow of approximately $3.016 million using the simple formula operating cash flow minus capital expenditure. That quarterly burn was material relative to available cash.

The March 2026 financing issued senior convertible notes with approximately $5.2 million principal for $4.3 million gross proceeds, reflecting a 20% original-issue discount. The notes mature September 11, 2026, with a company option to extend to December 11, 2026. In July 2026, Tenon completed a $4.2 million public offering and stated in a July 10 Form 8-K that it believed the offering restored compliance with Nasdaq’s minimum stockholders’ equity requirement, subject to continued monitoring.

What is the central financial trade-off?

Tenon has common stock plus Series A and Series B preferred shares that vote with common stock; the preferred shares carry 1.25 votes per share. The latest 2026 proxy statement measures ownership as of June 8, 2026, before the July public offering. This date distinction matters because subsequent issuance changes economic percentages.

What governance signals should researchers notice?

The board includes medical-device operators, a surgeon and finance experience, which is relevant for a highly specialized company. However, the Q1 2026 filing also states that disclosure controls were not effective because limited staffing prevented adequate segregation of accounting duties. For a small issuer that repeatedly raises capital and has complex warrants, preferred shares and convertible notes, that material weakness deserves attention.

Which growth drivers could change the scale of the business?

What could weaken the outlook?

Which KPIs matter for valuation?

A conventional terminal-growth DCF is difficult for Tenon because current free cash flow is negative and future dilution is material. The model should begin with operating drivers: procedure volume, revenue per procedure, gross margin, commercial productivity and cash burn. A scenario approach is more informative than a single precise forecast.

• Revenue growth: separate procedure growth from pricing, implant mix and acquisition contribution.
• Gross margin: test whether 60% FY2025 and 68.5% Q1 2026 represent sustainable scale economics.
• Operating leverage: compare gross-profit growth with sales, R&D and public-company expense growth.
• Reinvestment: include training, trials, tray sets, inventory and regulatory spending.
• Financing: model convertible conversion, warrants, preferred voting rights and future equity as part of per-share value.

Tenon Medical is a focused SI-joint fusion company with a more credible product platform than its small revenue base alone suggests. Catamaran and SImmetry+ give it two minimally invasive approaches; patents and clinical programs support differentiation; and Q1 2026 showed that procedure growth can produce meaningful gross-margin leverage.

The constraint is financial scale. Gross profit remains far below operating expense, cash burn is substantial, and financing has become a recurring part of the operating model. That means the central research question is not simply whether the devices work. It is whether Tenon can convert trained surgeons into repeat procedures quickly enough to outgrow its commercial and administrative cost base before further financing materially dilutes existing ownership.